{
    "ticker": "RVMDW",
    "name": "Reviva Pharmaceuticals Holdings, Inc.",
    "description": "Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders and other unmet medical needs. Founded in 2011 and headquartered in San Diego, California, Reviva aims to advance its proprietary drug candidates through clinical studies to provide safe and effective treatments for patients. The company's lead product candidate, RP5063, is being developed for the treatment of schizophrenia and other CNS disorders. This novel compound has shown promise in early clinical trials, demonstrating efficacy in reducing symptoms while maintaining a favorable safety profile. Reviva is committed to addressing serious health issues that impact millions of people and is exploring additional indications for its drug candidates. The company emphasizes a strategic approach to drug development, utilizing advanced technologies and rigorous clinical methodologies to ensure the success of its therapeutic innovations. With a dedicated team of experts in drug development, Reviva is poised to make significant contributions to the field of psychiatry and neurology, aiming to improve the quality of life for patients suffering from challenging conditions.",
    "industry": [
        "Biopharmaceutical",
        "Healthcare"
    ],
    "headquarters": "San Diego, California, USA",
    "founded": "2011",
    "website": "https://www.revivapharma.com",
    "ceo": "Laxminarayan B. B. K. Rao",
    "social_media": {
        "twitter": "https://twitter.com/RevivaPharma",
        "linkedin": "https://www.linkedin.com/company/reviva-pharmaceuticals/"
    },
    "investor_relations": "https://ir.reviva.pharma.com",
    "key_executives": [
        {
            "name": "Laxminarayan B. B. K. Rao",
            "position": "CEO"
        },
        {
            "name": "Kiran G. G. Rao",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "CNS Disorders",
            "products": [
                "RP5063"
            ]
        }
    ],
    "seo": {
        "meta_title": "Reviva Pharmaceuticals | Innovative CNS Treatments",
        "meta_description": "Reviva Pharmaceuticals is dedicated to developing innovative therapies for CNS disorders. Learn about our pipeline and commitment to advancing healthcare.",
        "keywords": [
            "Reviva Pharmaceuticals",
            "CNS Disorders",
            "Biopharmaceutical",
            "RP5063",
            "Schizophrenia",
            "Clinical Trials"
        ]
    },
    "faq": [
        {
            "question": "What does Reviva Pharmaceuticals do?",
            "answer": "Reviva Pharmaceuticals focuses on developing innovative therapies for central nervous system disorders and other unmet medical needs."
        },
        {
            "question": "What is Reviva's lead product candidate?",
            "answer": "Reviva's lead product candidate is RP5063, aimed at treating schizophrenia and other CNS disorders."
        },
        {
            "question": "Where is Reviva Pharmaceuticals headquartered?",
            "answer": "Reviva Pharmaceuticals is headquartered in San Diego, California, USA."
        },
        {
            "question": "When was Reviva Pharmaceuticals founded?",
            "answer": "Reviva Pharmaceuticals was founded in 2011."
        }
    ],
    "competitors": [
        "ACAD",
        "PTN",
        "SAGE",
        "VYNE"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "JNJ",
        "PFE"
    ]
}